FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects

Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.